文献速递关节外科

所有患者都应接受延长口服抗生素预防吗?明确其在初次及无菌翻修全关节置换术中的作用

Should All Patients Receive Extended Oral Antibiotic Prophylaxis? Defining Its Role in Patients Undergoing Primary and Aseptic Revision Total Joint Arthroplasty.
PubMed 文献 · J Arthroplasty · 2024-01-11

该回顾性研究纳入2016至2022年由同一位关节置换专科医生连续实施的2,982例初次(2,677例)与无菌翻修(305例)全关节置换术,自2020年1月起所有患者术后即口服头孢地尼300mg每日两次共7天;比较3个月假体周围感染率显示,接受延长口服抗生素预防者总体感染率显著低于未接受者(0.41%对1.13%,P=0.02)。

要点

  • 初次全关节置换术后接受延长口服抗生素者3个月假体周围感染率低于未接受者(0.23%对0.74%,P=0.04,OR 3.85)。
  • 无菌翻修全关节置换术后延长口服抗生素组感染率与未用组相比呈下降趋势但未达统计学显著(1.88%对4.83%,P=0.16,OR 2.71)。
  • 作者结论认为接受延长口服抗生素预防的初次及无菌翻修全关节置换患者3个月发生假体周围感染的可能性分别低3.85倍和2.71倍。

核心结论

  • 接受延长口服抗生素预防的初次全关节置换患者3个月假体周围感染的可能性为未接受者的3.85倍低(OR 3.85),无菌翻修患者为2.71倍低(OR 2.71)。
  • 作者指出需未来研究确定初次全关节置换术后3个月以后上述结果是否维持。

研究设计与样本

  • 回顾性综述,证据等级III。
  • 2016至2022年由同一位关节置换专科培训医生连续实施2,982例全关节置换,其中初次2,677例、无菌翻修305例。

主要发现

  • 初次与无菌翻修全关节置换合计,接受延长口服抗生素预防者3个月假体周围感染率0.41%,未接受者1.13%(P=0.02)。
  • 初次全关节置换后,接受延长口服抗生素预防者感染率0.23%,未接受者0.74%(P=0.04;OR 3.85)。
  • 无菌翻修全关节置换后,接受延长口服抗生素预防者感染率1.88%,未接受者4.83%(P=0.16;OR 2.71),呈下降趋势但未达统计学显著。

关键数值与推荐

  • 自2020年1月起,所有患者术后立即口服头孢地尼300mg,每日两次,共7天。

局限性

  • 原文为回顾性综述(证据等级III)。
  • 作者指出需未来研究确定初次全关节置换术后3个月以后上述结果是否维持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prior studies have demonstrated reduced periprosthetic joint infection (PJI) rates following extended oral antibiotics (EOAs) for high-risk patients undergoing primary total joint arthroplasty (TJA). This study compared 3-month PJI rates in all patients undergoing primary or aseptic revision TJA with or without EOA prophylaxis. METHODS: In total, 2,982 consecutive primary (n = 2,677) and aseptic revision (n = 305) TJAs were performed by a single, fellowship-trained arthroplasty surgeon from 2016 to 2022 were retrospectively reviewed. Beginning January 2020, all patients received 7 days of 300 mg oral cefdinir twice daily immediately postoperatively. Rates of PJI at 3 months were compared between patients who received or did not receive EOA. RESULTS: Rates of PJI at 3 months in patients undergoing primary and aseptic revision TJA were significantly lower in those receiving EOA prophylaxis compared to those who did not (0.41 versus 1.13%, respectively; P = .02). After primary TJA, lower PJI rates were observed with EOA prophylaxis utilization (0.23 versus 0.74%, P = .04; odds ratio [OR] 3.85). Following aseptic revision TJA, PJI rates trended toward a significant decrease with the EOA compared to without (1.88 versus 4.83%, respectively; P = .16; OR 2.71). CONCLUSIONS: All patients undergoing primary or aseptic revision TJA who received EOA prophylaxis were 3.85 and 2.71 times less likely, respectively, to develop PJI at 3 months compared to those without EOA. Future studies are needed to determine if these results are maintained at postoperative time periods beyond 3 months following primary TJA. LEVEL OF EVIDENCE: III, Retrospective review.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Bundschuh KE, Muffly BT, Ayeni AM, et al. Should All Patients Receive Extended Oral Antibiotic Prophylaxis? Defining Its Role in Patients Undergoing Primary and Aseptic Revision Total Joint Arthroplasty. J Arthroplasty. 2024. PMID: 38218558. doi:10.1016/j.arth.2024.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。